MinireviewSynthetic cannabinoids: Analysis and metabolites
Graphical abstract
Introduction
Synthetic cannabinoids, better referred to as cannabimimetic compounds, are compounds prepared by scientists around the world targeting an interaction with the endocannabinoid system, namely CB1 and CB2 receptors. Although many of these compounds have been described in the literature for many years, their illicit use appeared only in the last few years. They appeared in the United States market in late 2008. They were mixed with herbal products and sold as incense or potpourri on the internet, gas stations and tobacco shops under many brand names (Spice, Spice gold, Aroma, K2, Spike 99, etc.) with labels stating “not for human consumption”. These products are claimed to contain only natural non-illegal compounds and consequently have no limitations in their commercial distribution (Carroll et al., 2012). The consumption of these products has become a popular alternative to marijuana, as they are of high-potency and high efficacy as cannabinoid receptor full agonists.
The number of patients presented to the emergency department with problems associated with these drugs has dramatically increased. In March, 2011 the US Drug Enforcement Administration (DEA) scheduled five synthetic cannabinoids (JWH-018, JWH-073, JWH-200, CP-47,497, and CP-47,497 C8 homologue) as schedule 1 controlled substances. Many of these products especially Spice and K2 have been banned in many European countries (ElSohly et al., 2011, Wells and Ott, 2011) and in May 2013, three synthetic cannabinoids (UR-144, XLR-11 and AKB-48) were also placed in schedule 1.
Moreover, compared to THC, some synthetic cannabinoids possess a 4–5 times improved binding affinity to the cannabinoid CB1 receptor and many toxicity symptoms were reported including anxiety, paranoia, tachycardia, irritability, hallucination, numbness, seizures, high blood pressure, drowsiness, and slurred speech (Seely et al., 2012). Over the past few years a great effort has been exerted to identify and quantify synthetic cannabinoids in herbal products, and detect their metabolites in body fluids (urine, serum, and saliva) and also in hair specimens. These methods include liquid chromatography tandem mass spectroscopy (LC–MS/MS) (Teske et al., 2010), high mass resolution techniques like matrix-assisted laser desorption/ionization time of flight mass spectroscopy (MALDI-TOF) (Gottardo et al., 2012), direct analysis in real time mass spectrometry (DART-MS) (Musah et al., 2012), nuclear magnetic resonance (NMR) (Rollins et al., 2013), gas chromatography/mass spectrometry (GC/MS) (Sobolevskii et al., 2011), and immunoassays (Arntson et al., 2013).
Recently, many reviews on the chemistry, toxicity, and pharmacology of synthetic cannabinoids have been published (Carroll et al., 2012, Favretto et al., 2013, Seely et al., 2012, Spaderna et al., 2013, Wells and Ott, 2011). In this chapter, the focus will be on the analysis of the different classes of synthetic cannabinoids in herbal mixtures and the identification/analysis of their metabolites in biological fluids.
Synthetic cannabinoids can be chemically classified into naphthoylindoles, benzoylindoles, phenylacetylindoles, adamantylindoles, cyclophenols and a miscellaneous group. Different analytical techniques have been applied to the detection and quantitation of different members of each of these classes. Details are outlined below.
Section snippets
Liquid chromatography electrospray ionization tandem mass spectrometry (LC/MS/MS)
Since JWH-018 itself cannot be detected in urine, Möller et al. (2010) developed a method based on enzymatic hydrolysis followed by liquid–liquid extraction and LC/MS/MS analysis to detect its major metabolites in human urine for the purpose of doping control. After a successful confirmation of the JWH-018 phase-I metabolites, the method was then used in routine analysis of doping control samples.
Hutter et al. (2012) analyzed and screened the urine samples of patients who had consumed synthetic
LC/MS/MS
To analyze and screen urine samples of patients who had consumed synthetic cannabinoids, LC/MS/MS and HR/MS/MS were used (Hutter et al., 2012). JWH-250 and its metabolites were identified by ion spectra and mass measurements (Fig. 10).
Twenty-two metabolites of the synthetic cannabinoid JWH-250 (Fig. 11) in human urine and serum samples as well as in rat urine were identified by Grigoryev et al. (2011b). The consumption of JWH-250 can be established by detection of these metabolites in urine
LC/MS/MS
To analyze and screen the urine samples of patients who had consumed synthetic cannabinoids, HR/MS/MS was used (Hutter et al., 2012) and RCS-4 and its metabolites were identified by ion spectra and mass measurement (Fig. 13).
Ammann et al., 2012 developed and validated an LC/MS/MS method to detect the presence of 7 synthetic benzoylindoles (WIN 48,098, AM-1241, AM-694, RCS-4 C-4 homolog, RCS-4 2-methoxy homolog, RCS-4, and RCS-4 3-methoxy homolog) in blood samples (Table 3).
MALDI-TOF-MS
A MALDI-TOF-MS method
LC/MS/MS
A new designer drug found in illegal herbal products (sold in Japan) known as 6-methyl-2-[(4-methylphenyl)amino]-1-benzoxazin-4-one) (URB-754) was identified along with 5-fluoropentyl-3-pyridinoylindole, UR-144 and XLR-11 by UPLC/MS (Uchiyama et al. 2013).
Nico et al. (2013) analyzed eight herbal smoking blends and could identify UR-144 and XLR-11 along with 7 other synthetic cannabinoids by using EI/MS, and ESI/MS/MS. The compounds were isolated by column chromatography and their chemical
Concluding remarks
It is clear that the list of drugs with activity on the cannabinoid receptors is large and expanding every day. Many of these synthetic cannabinoids are finding their way into illicit markets as marijuana substitutes without any safety studies. The scientific community is continuing to generate new compounds and new chemical classes in their search for CB1 and CB2 antagonists for medicinal applications. It is anticipated that many of these compounds will find their way to the illicit market,
Conflict of interest statement
We, all four authors, have no conflict of interest.
References (47)
- et al.
Detection and quantification of new designer drugs in human blood: part 1 — synthetic cannabinoids
J Anal Toxicol
(2012) - et al.
Validation of a novel immunoassay for the detection of synthetic cannabinoids and metabolites in urine specimens
J Anal Toxicol
(2013) - et al.
MSE with mass defect filtering for in vitro and in vivo metabolite identification
Rapid Commun Mass Spectrom
(2007) - et al.
In vivo and in vitro metabolism of the synthetic cannabinoid JWH-200
Rapid Commun Mass Spectrom
(2013) - et al.
Designer drugs: a medicinal chemistry perspective
Ann N Y Acad Sci
(2012) - et al.
Simultaneous analysis of synthetic cannabinoids in the materials seized during drug trafficking using GC–MS
Anal Bioanal Chem
(2013) - et al.
Development and validation of a liquid chromatography–tandem mass spectrometry method for the quantitation of synthetic cannabinoids of the aminoalkylindole type and methanandamide in serum and its application to forensic samples
J Mass Spectrom
(2011) - et al.
Identification, extraction and quantification of the synthetic cannabinoid JWH-018 from commercially available herbal marijuana alternatives
Forensic Sci Int
(2012) - et al.
Liquid chromatography–tandem mass spectrometry analysis of urine specimens for K2 (JWH-018) metabolites
J Anal Toxicol
(2011) - et al.
New challenges and innovations in forensic toxicology: focus on the “new psychoactive substances”
J Chromatogr A
(2013)
First characterization of AKB-48 metabolism, a novel synthetic cannabinoid, using human hepatocytes and high-resolution mass spectrometry
AAPS J
Direct screening of herbal blends for new synthetic cannabinoids by MALDI-TOF MS
J Mass Spectrom
Screening for synthetic cannabinoids in hair by using LC–QTOF MS: a new and powerful approach to study the penetration of these new psychoactive substances in the population
Med Sci Law
Analysis of synthetic cannabinoids using high-resolution mass spectrometry and mass defect filtering: implications for nontargeted screening of designer drugs
Anal Chem
All-Russian conference ‘analytical chromatography and capillary electrophoresis’
Chromatography–mass spectrometry studies on the metabolism of synthetic cannabinoids JWH-018 and JWH-073, psychoactive components of smoking mixtures
J Chromatogr B
Gas and liquid chromatography–mass spectrometry studies on the metabolism of the synthetic phenylacetylindole cannabimimetic JWH-250, psychoactive component of smoking mixtures
J Chromatogr B
Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in ‘herbal mixtures’ using LC/MS/MS techniques
J Mass Spectrom
Characterization of in vitro metabolites of CP 47,497, a synthetic cannabinoid, in human liver microsomes by LC–MS/MS
J Forensic Sci
Analysis of 30 synthetic cannabinoids in serum by liquid chromatography–electrospray ionization tandem mass spectrometry after liquid–liquid extraction
J Mass Spectrom
LC/ESI–MS/MS method for quantification of 28 synthetic cannabinoids in neat oral fluid and its application to preliminary studies on their detection windows
Anal Bioanal Chem
Studies on the metabolism of JWH-018 and of a homologue of CP 47,497, pharmacologically active ingredients of different misused incense “spice” using GC/MS and LC/MS techniques
Ann Toxicol Anal
Identification of synthetic cannabinoids in herbal incense blends in the United States
J Forensic Sci
Cited by (106)
History of Cannabis Regulation and Medicinal Therapeutics: It's Complicated
2023, Clinical TherapeuticsCannabinoids as anticancer and neuroprotective drugs: Structural insights and pharmacological interactions—A review
2021, Process BiochemistryCitation Excerpt :Unfortunately, no SCB has been progressed to clinical use. Most of the SCBs were sprayed on dried plant materials or solubilized in liquids, and sold in the illicit markets for the end users to smoke or inhale [64,65]. They are marketed under the various names viz. “Spice”, “K2”, “Cloud 9”, “Mojo”, “Dreamer” etc [66,67].